Literature DB >> 12225905

Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence.

Xiong-Biao Wang1, Maria Kakoulidou, Ricardo Giscombe, Qianhui Qiu, DeRen Huang, Ritva Pirskanen, Ann Kari Lefvert.   

Abstract

Cytolytic T lymphocyte-associated antigen-4 (CTLA-4) plays a critical role in the down-regulation of antigen-activated immune responses. The aberrant CTLA-4 expression is characterized by low surface and intracellular levels of CTLA-4 protein, impaired up-regulation of CTLA-4 in T cells in response to ConA stimulation and high levels of soluble CTLA-4 (sCTLA-4) in serum. The serum levels of sCTLA-4 are positively correlated with the serum concentration of antibodies against the acetylcholine receptor. The (AT)(n) polymorphism in the 3'-untranslated region contributes to decreased mRNA stability and, hence, to reduced expression of CTLA-4.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12225905     DOI： 10.1016/s0165-5728(02)00228-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  36 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Natural evolution of hepatitis C virus infection in hemodialysis Tunisian patients and CTLA-4 SNP's.

Authors:  Leila Ksiaa Cheikhrouhou; Yousr Lakhoua-Gorgi; Imen Sfar; Salwa Jendoubi-Ayed; Houda Aouadi; Mouna Makhlouf; Khaled Ayed; Taieb Ben Abdallah
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

Review 3.  T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens.

Authors:  Syamal K Datta; Li Zhang; Luting Xu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

4.  Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.

Authors:  Zhao Xiaoyan; R Pirskanen; V Malmstrom; A K Lefvert
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 5.  Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Authors:  Rituparna Chakrabarti; Bhavya Kapse; Gayatri Mukherjee
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-07

6.  CTLA-4 and TNF-α promoter-308 A/G polymorphisms and ANCA-associated vasculitis susceptibility: a meta-analysis.

Authors:  Young Ho Lee; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

Review 7.  Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders.

Authors:  Bernadette Biondi; George J Kahaly; R Paul Robertson
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

8.  Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.

Authors:  Douglas B Johnson; Vita Saranga-Perry; Patrick J M Lavin; W Bryan Burnette; Stephen W Clark; David R Uskavitch; Deborah E Wallace; Mark A Dickson; Ragini R Kudchadkar; Jeffrey A Sosman
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

9.  Overexpression and secretion of the soluble CTLA-4 splice variant in various autoimmune diseases and in cases with overlapping autoimmunity.

Authors:  Suad AlFadhli
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-28

10.  Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity.

Authors:  Eric Toussirot; Philippe Saas; Marina Deschamps; Fabienne Pouthier; Lucille Perrot; Sylvain Perruche; Jacqueline Chabod; Pierre Tiberghien; Daniel Wendling
Journal:  Arthritis Res Ther       Date:  2009-07-01       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.